CSF3 and Miyoshi myopathy: Therefore, this phase 3 study (GENESIS) was designed to compare the safety and efficacy of motixafortide + G-CSF versus placebo + G-CSF in patients with MM undergoing HSPC mobilization before ASCT (NCT03246529).